Web Flow - Login to access your portal

New Operational Flexible Serialization Suite at Hay-on-Wye

PCI Pharma Services (PCI) are pleased to announce a significant expansion of our market-leading Serialization capability at our Hay-on-Wye site in the UK.

EU FMD Compliance ready at PCI Hay-On-Wye

The suite installation increases the site’s Serialization capability to support PCI’s clients in advance of meeting the implementation dates of the European Falsified Medicines Directive (EU FMD).

The highly flexible technology delivers machine and human-readable coding, tamper evident solutions and Bollini labelling – which in turn is linked to a case loading and aggregation station, with a final aggregation station compacting cases to pallet. PCI is a strong supporter of the advanced use of aggregation to realize the significant benefits in packaging operations, as well as the broader pharmaceutical supply chain.

PCI custom developed and engineered the enhanced Serialization solution to maximize flexibility and ease of use for a variety of client package styles and applications. The suite includes strategically located multi-position laser and thermal inkjet coding heads, with associated inspection cameras to deliver ultimate flexibility in configuration, location and type of coding. This includes multi-position tamper evident labelling heads to support a full service solution to satisfy the requirements of the EU FMD. The system is able to effectively manage a broad range of sizes and package styles, with significant high-speed application.

This investment in PCI’s Hay facility is the first phase of a multi-stage installation of expanded Serialization capacity at the site, complimenting a significant global initiative from PCI in developing its overall Serialization offering. In February 2017, PCI announced an investment that will triple its Serialization capacity across its global network in preparation for the pending DCSCA deadline in November this year.

PCI has been actively serializing commercial products for the US, European and international markets for the past five years, and this investment in the Hay-on-Wye capabilities continues to demonstrate PCI’s market-leading position. The company-wide software strategy enables operators in all PCI’s global locations to operate the same graphical user interface, providing a seamless global service.

PCI has partnered with Antares Vision, Crest Solutions and Xyntek for this latest installation, utilizing Antares’ leading Serialization platform and technology architecture. This installation supports a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.

Commenting on this latest investment, Colin White, PCI Managing Director, Hay-on-Wye, stated: “This is an important addition to the site’s capabilities. Patient safety and maintaining supply chain integrity is of critical importance. Our expertise based on real-life experience, combined with such significant strategic investment, delivers a truly industry-leading solution for our customers.

White continued: “Being able to offer this fully flexible service and work in partnership with our customers to deliver a trusted, seamless service is critical, and being ahead of the timelines with this offering ensures compliance with the EU FMD.

Posted on Categories News

Leave a Reply

Your email address will not be published. Required fields are marked *

16 + 8 =

Explore the PCI Process Phase by Phase

PRE-CLINICAL
PHASE I
PHASE II
PHASE III
COMMERCIAL

Swipe to explore the PCI Process

PRE CLINICAL

pre-clinical-icon
  • Formulation Development
  • Analytical development/characterisation

PHASE 1

PCI Phase 1
  • Formulation Development
  • Analytical Development
  • Drug in capsule/vial technology (Xcelodose)®
  • Phase I product manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase I packaging and labelling
  • Storage and distribution

PHASE 2

PCI Phase 2
  • Formulation Optimization
  • Dosage Form Process Validation
  • Analytical Testing and Stability Services
  • Phase II Product Manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase II packaging and labelling
  • Storage and distribution

PHASE 3

PCI Phase 3
  • Comparator Sourcing
  • Scale Up Studies
  • Phase III Product Manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase III packaging and labelling
  • Analytical testing and stability services
  • Storage and distribution

COMMERCIAL

PCI Commercial Phase
  • Scale up for commercial supply
  • Commercial product manufacture
  • Commercial packaging and labelling
  • Validation services
  • Analytical testing and stability services
  • Product release to market
  • Storage and distribution

PCI Points...

You told us what aspects you value as "very important" when choosing a vendor...

Why choose us...

Our global reach and localized support ensures PCI as a strategic partner remains focussed on delivering speed-to-market and the commercial success of our customers

PCI is a global company that focusses on delivering speed-to-market and the commercial success of our customers

Why choose us...